Vaxcyte
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Vaxcyte generated cash of -$296,790,000, which is less than the previous year. Cash used in financing activities reached the amount of $639,813,000 last year. Net change in cash is therefore -$436,974,000.
Cash Flow
| 2017 | -14.96K | -1.11K | 43.85K |
|---|---|---|---|
| 2018 | -30.46M | -1.77M | 62.19M |
| 2019 | -47.14M | -1.19M | 41.56M |
| 2020 | -46.62M | -1.10M | 374.87M |
| 2021 | -121.39M | -212.30M | 17.79M |
| 2022 | -170.59M | 74.58M | 861.54M |
| 2023 | -296.79M | -773.31M | 639.81M |
PCVX Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 835.52M | 69.85M | 386.2M | 58.97M | 66.09M | 36.13M | 8.35K |
Operating activities | |||||||
Net income | -402.26M | -223.48M | -100.07M | -89.21M | -50.27M | -29.48M | -17.23K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 10.17M | 9.19M | 3.45M | 1.40M | 1.23M | 1.03M | 625 |
Stock-based compensation expense | 48.76M | 23.65M | 10.72M | 5.43M | 1.18M | 0 | 390 |
| Deferred income tax benefit | 48.76M | 23.65M | 10.72M | 5.43M | 1.18M | 0 | 390 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 868K | 1.26M | 0 |
Inventories | 0 | 0 | 0 | 0 | 2.87M | -1.18M | 0 |
Accounts payable | 11.22M | 2.89M | -12.47M | 26.10M | 868K | 1.26M | 0 |
Cash generated by operating activities | -296.79M | -170.59M | -121.39M | -46.62M | -47.14M | -30.46M | -14.96K |
Investing activities | |||||||
Purchases Of Investments | -1.32B | -102.74M | -336.34M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -67.87M | -5.84M | -6.55M | -1.15M | -1.19M | -1.77M | -1.22K |
Acquisitions Net | 0 | 7K | 26K | 50K | 0 | 1K | 0 |
Cash generated by investing activities | -773.31M | 74.58M | -212.30M | -1.10M | -1.19M | -1.77M | -1.11K |
Financing activities | |||||||
Common Stock Issued | 636.04M | 856.48M | 17.79M | 267.37M | 42.94M | 62.47M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 374K | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -61K | -278K | -283K | -188K |
Cash used in financing activities | 639.81M | 861.54M | 17.79M | 374.87M | 41.56M | 62.19M | 43.85K |
Net Change In Cash | -436.97M | 765.67M | -316.34M | 327.22M | -7.11M | 29.95M | 27.78K |
Cash at end of period | 398.55M | 835.52M | 69.85M | 386.2M | 58.97M | 66.09M | 36.13K |
| Data source | Data source | Data source | Data source |